Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 1;22(4):250-256.
doi: 10.1097/ACI.0000000000000838.

Secondary prevention of latex allergy

Eustachio Nettis  1 , Rossella Casella  1 , Cristoforo Incorvaia  2 , Andrea Miniello  1
Affiliations
Review

Secondary prevention of latex allergy

Eustachio Nettis et al. Curr Opin Allergy Clin Immunol. .

Abstract

Purpose of review: The present review addresses the secondary prevention in healthcare worker, healthcare setting, and in patients outside the healthcare setting.

Recent findings: There is sufficient knowledge of the broad aetiology of latex allergy for secondary preventive programmes to be widely adopted. Currently, avoidance of latex-containing surgical products is mandatory in the care of sensitized patients. They should also have a list of occult sources of natural rubber latex exposure and cross-reacting fruits. During all health-care procedures latex allergic patients should be treated in a 'latex-free' environment. Specific sublingual immunotherapy has been suggested as a suitable therapeutic option. It can be offered, in addition to symptomatic treatment, to selected patients, when avoidance measures are not feasible or effective. The use of omalizumab could also be extended as an adjunct to latex immunotherapy.

Summary: Despite of the progress made in the secondary prevention of latex allergy, the disease still continues to be a global health problem.

PubMed Disclaimer

References

    1. Ownby DR. A history of latex allergy. J Allergy Clin Immunol 2002; 110:S27–32.
    1. Cabanes N, Igea JM, de la Hoz B, et al. Committee of Latex Allergy; SEAIC Latex allergy: Position Paper. J Investig Allergol Clin Immunol 2012; 22:313–330.
    1. Raulf M. Current state of occupational latex allergy. Curr Opin Allergy Clin Immunol 2020; 20:112–116.
    1. Warshaw HM. Latex allergy. J A Acad Dermatol 1998; 39:1–24.
    1. Jaeger D, Kleinhans D, Czuppon AB, Baur X. Latex-specific proteins causing immediate-type cutaneous, nasal, bronchial, and systemic reactions. J Allergy Clin Immunol 1992; 9:501–507.